Publications by Career Development Program Trainees

Grant Cycle One (2001-2006)

Publications

  1. Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.  Prostate 52:20-33, 2002.
    PMID: 11992617
  2. Tiguert, R., Lessard, A., So, A., and Fradet, Y. Prognostic markers in muscle invasive bladder cancer.  World J Urol 20: 190-195, 2002.
    PMID: 12196903
  3. So, A., Hickey, L., and Norman, R. Late ureteral conduit urinary leak as a presentation of urothelial carcinoma of the ureter.  Urol 59: 946, 2002; Urol Review Journal 4: 20-21, 2003
    PMID: 12031389
  4. So, A., Goldenberg, L., and Gleave, M.E. Prostate specific antigen: an updated review. Can J Urol 10: 2040-2050, 2003.
    PMID: 14704108
  5. So, A., Hurtado-Coll, A., and Gleave, M.E. Androgens and prostate cancer. World J Urol 21: 325-327, 2003.
    PMID: 14586548
  6. So, A., and Paterson, R.F. Gross hematuria in a man with normal renal function (case review).  Renal and Urology News, 2003
  7. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 9:295-306, 2003.
    PMID: 12538482
  8. Roudier MP, Vesselle H, True LD, Higano CS, Ott SM, King SH, Vessella RL. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.  Clin and Exp Metastasis 20:171-180, 2003
    PMID: 12705638
  9. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange PH, Vessella RL. Phenotypic  heterogeneity of end-stage prostate carcinoma metastatic to bone. Human Path. 34:646-653, 2003
    PMID: 12874759
  10. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with RT-PCR for the detection of micrometastatic prostate cancer in lymph nodes.  Cancer Res. 63:4662-4670, 2003
    PMID: 12907647
  11. Roudier MP, True LD, Vessella RL, Higano CS. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.  Journal of Clin. Path. 57:321-323, 2004
    PMID: 14990610
  12. Roudier MP, Corey E, True LD,  Higano CS, Ott SM, Vessella RL.  Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases.  Ed. E Keller and L Chung. The Biology of Skeletal Metastases, Kluwer Academic Publishers, Boston, pp 311-339, 2004.
    PMID: 15043198
  13. Cheteri, M.B., Stanford, J.L., Friedrichsen, D., Peters, M.A., Iwasaki, L., et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 59: 409-418, 2004.
    PMID: 15065089
  14. July, L.V., Beraldi, E., So, A., Evans, K., English, J., Fazli, L., and Gleave, M.E. Nucleotide-based therapies targeting clusterin chemosensitizes human lung adenocarcinoma cells both in vitro and in vivo. Molecular Cancer Therapeutics 3: 223-232, 2004
    PMID: 15026542
  15. Rocchi, P., So, A., Kojima, S., Signaevsky, M., Beraldi, E., Fazli, L., Hurtado-Coll, A., Yamanaka, K., and Gleave, M.E. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone refractory prostate cancer.  Cancer Res 64: 6595-602, 2004.
    PMID: 15374973
  16. Miyake, H., Eto, H., Hara, I., So, A., Li, D., and Gleave, M.E. Synergistic antitumor activity by combine4d treatment with Gemcitabine and anti-sense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer KoTCC-1 cells.  J Urol 171: 2477-2481, Comment 2482-3. 2004.
    PMID: 15126879
  17. So, A., Bowden, M., and Gleave, M.E. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionigi tumours. Brit J Urol.93: 845-850, 2004
    PMID: 15050003
  18. Trougakos, I., So, A., Jansen, B., Gleave, M.E., and Gonos, E.S. Silencing expression of the clusterin/apolipoprotein J gene human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability and cell sensitization to genotoxic and oxidative stress. Cancer Res. 64:1834-1842, 2004.
    PMID: 14996747
  19. Rocchi, P., Muracciole, X., Fina, F., Mulholland, D., Karsenty, G., Palmari, J., Bladou, F., and Martin, P.M. Molecular analsis of androgen independent progression of prostatic carcinoma in vivo LuCaP23.1 xenograft.  Oncogene 56: 9111-9119, 2004.
    PMID: 15489889
  20. Lai, J.S., Brown, L.G., True, L.D., Hawley, S.J., Etzioni, R.B., Higano, C.S., Ho, S.M., Vessella, R.L., and Corey, E. Metastases of prostate cancer express estrogen receptor-beta. Urology, 64: 814-820, 2004.
    PMID: 15491740
  21. Eigl BJC, Eggener SE, Baybik J, Ettinger J, Chi KN, Nelson C, Wang Z, Gleave ME. Timing is everything: Preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin. Cancer Res. 2005 11: 4905-4911.
    PMID: 16000589
  22. Miyake H, Hara I, Yamanaka K, Muramaki M, Gleave M, Eto H. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential.  Oncol Rep. 13: 341-345, 2005.
    PMID: 15643522
  23. Miyake H, Yamanaka K, Muramaki M, Kurahashi T, Gleave M, Hara I: Enhanced expression of the secreted form of cluserin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer. Oncol Rep. 5:1371-1375, 2005.
    PMID: 16211311
  24. Yamanaka K, Gleave M, Muramaki M, Hara I, Miyake H. Enhanced radiosensitivity by inhibition of the anti-apoptotic gene clusterin using antisense oligodeoxynucleotide in a human bladder cancer model. Oncol Rep. 5: 885-90, 2005
    PMID: 15809754
  25. Yamanaka K, Gleave ME, Hara I, Muramaki M, Miyake H. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther. 2:187-195, 2005.
    PMID: 15713890
  26. Yamanaka, K., Rocchi, P., Miyake, H., Fazil, L., Vessella, R., Zangemeister-Wittke, U., and Gleave, M.E. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther. 11: 1689-1698, 2005.
    PMID: 16275990
  27. Taieb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, and Vasseur S.  Inactivation of the stress protein p8 increases carbon tetrachloride hepatotoxicity through alteration of CYP2E1 inhibition.  Hepathology 42: 176-182, 2005.
    PMID: 15962327
  28. Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C, and Gleave M.  Increased Hsp27 after androgen ablation facilitates androgen independent progression in prostate cancer via stat3-medicated suppression of apoptosis.  Cancer Res. 65: 11083-11093, 2005.
    PMID: 16322258
  29. Fina F, Muracciole X, Rocchi P, Nanni-Metellus I, Delfino C, Daniel L, Dussett C, Ouafik LH, and Martin PM. Molecular profile of androgen-independent prostate cancer xenograft LuCaP23.1.  Journal Steroid Biochem Mol Biol. 96: 355-365, 2005.
    PMID: 16043352
  30. So, A., Sinnemann, S., Huntsman, D., Fazli, L., and Gleave, M. Knockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivo.  Mol Cancer Ther. 4: 1837-1849, 2005.
    PMID: 16373699
  31. So, A., Rocchi, P., and Gleave, M. Antisense oligonucleotide therapy in the management of bladder cancer. Current Opinion in Urol. 15: 320-327, 2005
    PMID: 16093856
  32. So, A., Hurtado, A., Gleave, M.E., and Nelson, C. Mechanisms of the development of androgen independence in prostate cancer.  World J Urol. 2005 Feb;23(1):1-9
    PMID: 15770516
  33. Roudier, M.P., Bain, S.D., and Dougall, W.C. Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.  Clin Exp Metastasis: 2006;23(3-4):167-75
    PMID: 16912914
  34. Yamanaka, K., Rocchi, P., Miyake, H., Fazil,L., So, A., Zangemeister-Wittke, U., and Gleave, M. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligoniucleotide targeting Bcl-2 and Bcl-xl genes.  British J of Urol 97: 1300-1308, 2006
    PMID: 16686729
  35. Moore S, Knudsen B, True LD, Hawley S, Etzioni R, Wade C, Gifford D, Coleman I, Nelson PS. Loss of stearoyl-CoA desaturase expression is a frequent event in prostate carcinoma. International Journal Cancer 114: 563-571, 2006.
    PMID: 15609334
  36. Bavik, C., Coleman I, Dean, J.P., Knudsen. B., Plymate, S., and Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Research 66: 794-802, 2006.
    PMID: 16424011
  37. Rauch, A., Bellew, M., Eng, J., Fitzgibbon, M., Holzman, T., Hussey, P., Igra, M., MacLean, B., Lin, C.W., Detter, A., Fang. R., Faca, V., Gafken, P., Zhang, H., Whiteaker, J., States, D., Hanash, S., Paulovich, A., and McIntosh, M. Computational proteomics analysis system (CPAS): an extensible, open-source analytic system for evaluating and publishing proteomic data and high throughput biological experiments. J Proteome Res 5: 112-121, 2006.
    PMID: 16396501
  38. Bellew,M., Coram, M., Fitzgibbon, M., Igra, M., Randolph,T., Wang, P., May, D., Eng, J., Fang, R., Lin, C.W., Chen, J., Goodlet, D., Whiteaker, J., Paulovich, A., and McIntosh, M.  A suite of algorithms for the comprehensive analysis of complex protein mixtures using high-resolution LC-MS. Bioinformatics 22: 1902-1909, 2006
    PMID: 16766559
  39. Rocchi P, Jugpal P, So A, Sinneman S, Ettinger S, Fazli L, Nelson C, and Gleave M.  Small interference RNA targeting heat shock protein 27 inhibits the growth of Prostatic cell lines and induces apoptosis via cespase-3 activation in vitro.  British J of Urol. 2006 Nov;98(5):1082-9
    PMID: 16879439
  40. Agalliu, I., Lin, D.W., Salinas, C.A., Feng, Z., and  Stanford, J.L. Polymorphisms in the glutathione S-trasferase M(1), T(12), and P(1) genes and prostate cancer prognosis. Prostate 66: 1535-1541, 2006.
    PMID: 16921513
  41. Salinas, C.A., Agalliu, I., Stanford, J.L., and Lin. D.W. Statins and the risk of cancer. JAMA 295: 2721-2722, 2006.
    PMID: 16788124
  42. Agalliu, I., Langeberg, W.J., Lampe, J.W., Salinas, C.A., Lampe, J.W., Salinas, C.A., and Stanford, J.L. Glutathione S-transferase M1. T1, and P1 polymorphisms and prostate cancer risk in middle-aged men.  Prostate 66: 146-156, 2006.
    PMID: 16173036
  43. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66: 971-86, 2006.
    PMID: 16541420
  44. True. L., Coleman, I., Hawley, S., Huang, C.Y., Gifford, D., Coleman, R., Beer, T.M., Gelmann, E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. Related articles, Links. A molecular correlate to the Gleason grading system for  prostate adenocarcinoma. Proceedings of the National Academy of Science USA 103 (29):10991-6, 2006
    PMID: 16829574
  45. Page, S.T., Lin,D.W., Mostaghel, E.A., Hess, D.L., True, L.D., Amory, J.K., Nelson, P.S., Matsumoto, A.M., and Bremner, W.J. Persistent intraprostatic androgen concentration after medical castration in healthy men. Journal of Clinical Endocrinology and Metabolism 2006 Oct;91(10):3850-6
    PMID: 16882745
  46. Marks LS, Mazer NA, Mostaghel EA, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov D, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.  Journal of the American Medical Association. 2006 Nov 15;296(19):2351-61.
    PMID: 17105798
  47. Gong, Z., Neuhouser, M.L., Goodman, P.J., Albanes, D., Chi, C., Hsing., A.W., Lippman S.M., Platz, E.A., Pollak, M.N., Thompson, I.M., and Kristal, A.R. Obesity, diabetes, and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 2006 Oct;15(10):1977-83.
    PMID: 17035408
  48. Gong, Z., Agalliu, I., Lin, D.W., Stanford, J.L., and Kristal, A.R. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007 Mar 15;109(6):1192-202
    PMID: 17311344
  49. Inoue, L.Y., Neira, M., Nelson, C.C., Gleave, M.E., Etzioni, R. Cluster-based Network models for time-course gene expression data. Biostatistics 2007 Jul; 8(3):507-25
    PMID: 16980695 

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.

CenterNetCheck E-mail